Dr. Alexander Abrams is a Patent Agent in the Intellectual Property Practice of the firm's New York office and focuses his practice on patent prosecution, freedom-to-operate analysis, and patentability assessment. He works with corporations, start-ups, and universities in patent drafting and prosecution of patent families (domestic and international). His experience is in life science including genome sequencing (Next-Generation and Nanopore), gene therapy constructs, purification of viral vectors (e.g., chromatography), gene-editing tools (e.g., CRISPR), production of antibodies, chimeric antigen receptor T-cell therapy (CAR-T), oncology, clinical trials, diagnostic imaging (e.g., MRI), and medical devices.

Prior to joining Baker Botts, Dr. Abrams was a genetic variant scientist at GeneDx, where he analyzed and interpreted DNA sequencing data (e.g., Next-Gen, SNP array) to identify mutations in patients with rare genetic disease, mitochondrial diseases, and developmental disorders. As a post doc at Yale University, he developed cell sorting and single-cell-type sequencing (e.g., 10x Genomics) methodologies to understand the diversity of neurons. In addition, he worked as a consultant on projects to identify potential drugs from available clinical trial disclosures. As a graduate student at the University of Miami, he utilized exome sequence to identify and functionally characterized several novel disease genes involved in neuronal maintenance.